Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using ipilimumab and nivolumab has recently been approved as a frontline therapy, but this led to only a small improveme...
Gespeichert in:
| Veröffentlicht in: | Cancer research communications Jg. 4; H. 1; S. 18 - 27 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
American Association for Cancer Research
03.01.2024
|
| Schlagworte: | |
| ISSN: | 2767-9764, 2767-9764 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using ipilimumab and nivolumab has recently been approved as a frontline therapy, but this led to only a small improvement in overall patient survival. As more than half of patients with mesothelioma have alterations in the gene encoding for BAP1 this could be a potential marker for targeted therapies. In this study, we investigated the synergistic potential of combining EZH2 inhibition together with FGFR inhibition for treatment of BAP1-deficient malignancies. The efficacy of the combination was evaluated using human and murine preclinical models of mesothelioma and uveal melanoma in vitro. The efficacy of the combination was further validated in vivo by using BAP1-deficient mesothelioma xenografts and autochthonous mouse models. In vitro data showed sensitivity to the combined inhibition in BAP1-deficient mesothelioma and uveal melanoma tumor cell lines but not for BAP1-proficient subtypes. In vivo data showed susceptibility to the combination of BAP1-deficient xenografts and demonstrated an increase of survival in autochthonous models of mesothelioma. These results highlight the potential of this novel drug combination for the treatment of mesothelioma using BAP1 as a biomarker. Given these encouraging preclinical results, it will be important to clinically explore dual EZH2/FGFR inhibition in patients with BAP1-deficient malignant mesothelioma and justify further exploration in other BAP1 loss-associated tumors.
Despite the recent approval of immunotherapy, malignant mesothelioma has limited treatment options and poor prognosis. Here, we observe that EZH2 inhibitors dramatically enhance the efficacy of FGFR inhibition, sensitising BAP1-mutant mesothelioma and uveal melanoma cells. The striking synergy of EZH2 and FGFR inhibition supports clinical investigations for BAP1-mutant tumors. |
|---|---|
| AbstractList | Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using ipilimumab and nivolumab has recently been approved as a frontline therapy, but this led to only a small improvement in overall patient survival. As more than half of patients with mesothelioma have alterations in the gene encoding for BAP1 this could be a potential marker for targeted therapies. In this study, we investigated the synergistic potential of combining EZH2 inhibition together with FGFR inhibition for treatment of BAP1-deficient malignancies. The efficacy of the combination was evaluated using human and murine preclinical models of mesothelioma and uveal melanoma in vitro. The efficacy of the combination was further validated in vivo by using BAP1-deficient mesothelioma xenografts and autochthonous mouse models. In vitro data showed sensitivity to the combined inhibition in BAP1-deficient mesothelioma and uveal melanoma tumor cell lines but not for BAP1-proficient subtypes. In vivo data showed susceptibility to the combination of BAP1-deficient xenografts and demonstrated an increase of survival in autochthonous models of mesothelioma. These results highlight the potential of this novel drug combination for the treatment of mesothelioma using BAP1 as a biomarker. Given these encouraging preclinical results, it will be important to clinically explore dual EZH2/FGFR inhibition in patients with BAP1-deficient malignant mesothelioma and justify further exploration in other BAP1 loss-associated tumors.
Despite the recent approval of immunotherapy, malignant mesothelioma has limited treatment options and poor prognosis. Here, we observe that EZH2 inhibitors dramatically enhance the efficacy of FGFR inhibition, sensitising BAP1-mutant mesothelioma and uveal melanoma cells. The striking synergy of EZH2 and FGFR inhibition supports clinical investigations for BAP1-mutant tumors. Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using ipilimumab and nivolumab has recently been approved as a frontline therapy, but this led to only a small improvement in overall patient survival. As more than half of patients with mesothelioma have alterations in the gene encoding for BAP1 this could be a potential marker for targeted therapies. In this study, we investigated the synergistic potential of combining EZH2 inhibition together with FGFR inhibition for treatment of BAP1-deficient malignancies. The efficacy of the combination was evaluated using human and murine preclinical models of mesothelioma and uveal melanoma in vitro. The efficacy of the combination was further validated in vivo by using BAP1-deficient mesothelioma xenografts and autochthonous mouse models. In vitro data showed sensitivity to the combined inhibition in BAP1-deficient mesothelioma and uveal melanoma tumor cell lines but not for BAP1-proficient subtypes. In vivo data showed susceptibility to the combination of BAP1-deficient xenografts and demonstrated an increase of survival in autochthonous models of mesothelioma. These results highlight the potential of this novel drug combination for the treatment of mesothelioma using BAP1 as a biomarker. Given these encouraging preclinical results, it will be important to clinically explore dual EZH2/FGFR inhibition in patients with BAP1-deficient malignant mesothelioma and justify further exploration in other BAP1 loss-associated tumors.Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using ipilimumab and nivolumab has recently been approved as a frontline therapy, but this led to only a small improvement in overall patient survival. As more than half of patients with mesothelioma have alterations in the gene encoding for BAP1 this could be a potential marker for targeted therapies. In this study, we investigated the synergistic potential of combining EZH2 inhibition together with FGFR inhibition for treatment of BAP1-deficient malignancies. The efficacy of the combination was evaluated using human and murine preclinical models of mesothelioma and uveal melanoma in vitro. The efficacy of the combination was further validated in vivo by using BAP1-deficient mesothelioma xenografts and autochthonous mouse models. In vitro data showed sensitivity to the combined inhibition in BAP1-deficient mesothelioma and uveal melanoma tumor cell lines but not for BAP1-proficient subtypes. In vivo data showed susceptibility to the combination of BAP1-deficient xenografts and demonstrated an increase of survival in autochthonous models of mesothelioma. These results highlight the potential of this novel drug combination for the treatment of mesothelioma using BAP1 as a biomarker. Given these encouraging preclinical results, it will be important to clinically explore dual EZH2/FGFR inhibition in patients with BAP1-deficient malignant mesothelioma and justify further exploration in other BAP1 loss-associated tumors.Despite the recent approval of immunotherapy, malignant mesothelioma has limited treatment options and poor prognosis. Here, we observe that EZH2 inhibitors dramatically enhance the efficacy of FGFR inhibition, sensitising BAP1-mutant mesothelioma and uveal melanoma cells. The striking synergy of EZH2 and FGFR inhibition supports clinical investigations for BAP1-mutant tumors.SIGNIFICANCEDespite the recent approval of immunotherapy, malignant mesothelioma has limited treatment options and poor prognosis. Here, we observe that EZH2 inhibitors dramatically enhance the efficacy of FGFR inhibition, sensitising BAP1-mutant mesothelioma and uveal melanoma cells. The striking synergy of EZH2 and FGFR inhibition supports clinical investigations for BAP1-mutant tumors. Malignant mesothelioma is a highly aggressive tumor with a survival of only 4–18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using ipilimumab and nivolumab has recently been approved as a frontline therapy, but this led to only a small improvement in overall patient survival. As more than half of patients with mesothelioma have alterations in the gene encoding for BAP1 this could be a potential marker for targeted therapies. In this study, we investigated the synergistic potential of combining EZH2 inhibition together with FGFR inhibition for treatment of BAP1-deficient malignancies. The efficacy of the combination was evaluated using human and murine preclinical models of mesothelioma and uveal melanoma in vitro. The efficacy of the combination was further validated in vivo by using BAP1-deficient mesothelioma xenografts and autochthonous mouse models. In vitro data showed sensitivity to the combined inhibition in BAP1-deficient mesothelioma and uveal melanoma tumor cell lines but not for BAP1-proficient subtypes. In vivo data showed susceptibility to the combination of BAP1-deficient xenografts and demonstrated an increase of survival in autochthonous models of mesothelioma. These results highlight the potential of this novel drug combination for the treatment of mesothelioma using BAP1 as a biomarker. Given these encouraging preclinical results, it will be important to clinically explore dual EZH2/FGFR inhibition in patients with BAP1-deficient malignant mesothelioma and justify further exploration in other BAP1 loss–associated tumors. |
| Author | van Lohuizen, Maarten Berns, Anton Badhai, Jitendra Hulsman, Danielle Krijgsman, Oscar Song, Ji-Ying Pandey, Gaurav Kumar Chandrasekaran, Gayathri Landman, Nick |
| AuthorAffiliation | 3 Department of Zoology, Banaras Hindu University, Varanasi, India 4 Department of Experimental Animal Pathology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands 2 Oncode Institute, Jaarbeursplein, Utrecht, the Netherlands 1 Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands 5 Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands |
| AuthorAffiliation_xml | – name: 4 Department of Experimental Animal Pathology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands – name: 2 Oncode Institute, Jaarbeursplein, Utrecht, the Netherlands – name: 1 Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands – name: 5 Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands – name: 3 Department of Zoology, Banaras Hindu University, Varanasi, India |
| Author_xml | – sequence: 1 givenname: Jitendra orcidid: 0000-0002-9526-3748 surname: Badhai fullname: Badhai, Jitendra – sequence: 2 givenname: Nick orcidid: 0000-0001-9473-4686 surname: Landman fullname: Landman, Nick – sequence: 3 givenname: Gaurav Kumar orcidid: 0000-0002-4372-9331 surname: Pandey fullname: Pandey, Gaurav Kumar – sequence: 4 givenname: Ji-Ying orcidid: 0000-0002-6296-1996 surname: Song fullname: Song, Ji-Ying – sequence: 5 givenname: Danielle orcidid: 0000-0001-9347-8553 surname: Hulsman fullname: Hulsman, Danielle – sequence: 6 givenname: Oscar orcidid: 0000-0003-0825-3291 surname: Krijgsman fullname: Krijgsman, Oscar – sequence: 7 givenname: Gayathri orcidid: 0009-0009-8276-2562 surname: Chandrasekaran fullname: Chandrasekaran, Gayathri – sequence: 8 givenname: Anton orcidid: 0000-0003-2194-1988 surname: Berns fullname: Berns, Anton – sequence: 9 givenname: Maarten orcidid: 0000-0001-6877-2873 surname: van Lohuizen fullname: van Lohuizen, Maarten |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38054839$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtv1TAQhS1URB_0J4C8ZJPiZ-yIBSpRb1upFajABiFZju3cOyixS5xbqf8eRy1XhU1XHs2cc2bk7xDtxRQDQm8oOaFU6vdM1apqVC1O2pu2YrwipfMCHez6e0_qfXSc8y9CikYJWfNXaJ9rIoXmzQH62aaxgxg8vowb6GCGFHHq8dmPC4Zt9Hh1vrrBkPHX-ximNeQZHIaIP51-oZUPPTgIccbXdoB1tEsVcpo3YYA02tfoZW-HHI4f3yP0fXX2rb2orj6fX7anV5UTVMxVz5xzoWNSBSW8lLL2XjvSk5oFLQJXnIpOWOm0ZZKoXnrqCLHa-4bQhnh-hD4-5N5uuzF4Vy6a7GBuJxjtdG-SBfPvJMLGrNOdoUTVXHJSEt49Jkzp9zbk2YyQXRgGG0PaZsN0oxspakKL9O3TZbstf_-0COSDwE0p5yn0OwklZsFnFjRmQWMKPsO4WfAV34f_fA5muwApN8PwjPsPYaOfvw |
| CitedBy_id | crossref_primary_10_3390_cancers16111971 crossref_primary_10_3390_cancers17091581 crossref_primary_10_1038_s41571_024_00972_1 crossref_primary_10_1016_j_bbcan_2025_189267 |
| Cites_doi | 10.1016/S0140-6736(20)32714-8 10.1038/nrc2736 10.1016/S1470-2045(22)00277-7 10.1186/s13059-014-0550-8 10.1038/232054a0 10.1158/1078-0432.CCR-21-1466 10.1016/0166-3542(90)90001-N 10.1158/1078-0432.CCR-17-1172 10.1038/nrm4067 10.1371/journal.pone.0092444 10.1073/pnas.0806213105 10.1097/JTO.0000000000000471 10.1016/j.lungcan.2019.12.018 10.1016/j.lungcan.2016.12.004 10.1016/S0140-6736(10)60251-6 10.1186/1479-5876-10-179 10.1016/j.xcrm.2022.100915 10.1038/nm.3947 10.1084/jem.20191257 10.1038/modpathol.2016.188 10.1016/j.jtho.2016.12.019 10.1038/ng.855 10.1038/nature08966 10.1038/nrc1991 10.1200/JCO.2022.40.16_suppl.3122 10.1038/ng.912 10.1126/science.2168090 10.1056/NEJMra050152 10.1016/j.lungcan.2012.02.022 10.1038/ng.3520 |
| ContentType | Journal Article |
| Copyright | 2024 The Authors; Published by the American Association for Cancer Research. 2024 The Authors; Published by the American Association for Cancer Research 2024 Copyright held by the owner/author(s). |
| Copyright_xml | – notice: 2024 The Authors; Published by the American Association for Cancer Research. – notice: 2024 The Authors; Published by the American Association for Cancer Research 2024 Copyright held by the owner/author(s). |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1158/2767-9764.CRC-23-0276 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Inhibition of EZH2 and FGFR Synergizes in BAP1-deficient MM |
| EISSN | 2767-9764 |
| EndPage | 27 |
| ExternalDocumentID | PMC10763530 38054839 10_1158_2767_9764_CRC_23_0276 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Oncode Institute grantid: P2019 – fundername: KWF Kankerbestrijding (DCS) grantid: KWF,Grant # 11700 – fundername: EC | European Research Council (ERC) grantid: 319661 COMBATCANCER – fundername: ; grantid: P2019 – fundername: ; grantid: KWF,Grant # 11700 – fundername: ; grantid: 319661 COMBATCANCER |
| GroupedDBID | 53G AAYXX ALMA_UNASSIGNED_HOLDINGS CITATION EBS GROUPED_DOAJ M~E OK1 RCR RPM W2D CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c414t-f2ccceb257e74d5556dd8c0f062e84e37314b4a5c8a2507f5d1c00a8dd90190d3 |
| ISICitedReferencesCount | 4 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001154251800002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2767-9764 |
| IngestDate | Tue Sep 30 17:10:26 EDT 2025 Thu Jul 10 17:02:01 EDT 2025 Thu Apr 03 07:04:32 EDT 2025 Sat Nov 29 02:19:46 EST 2025 Tue Nov 18 20:44:36 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2024 The Authors; Published by the American Association for Cancer Research. This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c414t-f2ccceb257e74d5556dd8c0f062e84e37314b4a5c8a2507f5d1c00a8dd90190d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 J. Badhai and N. Landman Contributed equally to this article. |
| ORCID | 0000-0002-4372-9331 0000-0003-2194-1988 0000-0002-9526-3748 0000-0003-0825-3291 0000-0001-9473-4686 0000-0001-6877-2873 0009-0009-8276-2562 0000-0001-9347-8553 0000-0002-6296-1996 |
| OpenAccessLink | http://dx.doi.org/10.1158/2767-9764.CRC-23-0276 |
| PMID | 38054839 |
| PQID | 2898954601 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10763530 proquest_miscellaneous_2898954601 pubmed_primary_38054839 crossref_primary_10_1158_2767_9764_CRC_23_0276 crossref_citationtrail_10_1158_2767_9764_CRC_23_0276 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-03 |
| PublicationDateYYYYMMDD | 2024-01-03 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer research communications |
| PublicationTitleAlternate | Cancer Res Commun |
| PublicationYear | 2024 |
| Publisher | American Association for Cancer Research |
| Publisher_xml | – name: American Association for Cancer Research |
| References | Cheng (2024010314073775100_bib13) 1994; 54 Bott (2024010314073775100_bib16) 2011; 43 Nasu (2024010314073775100_bib14) 2015; 10 Laurie (2024010314073775100_bib26) 2017; 104 Badhai (2024010314073775100_bib23) 2020; 217 Herold (2024010314073775100_bib29) 2008; 105 Lam (2024010314073775100_bib27) 2020; 140 Love (2024010314073775100_bib32) 2014; 15 Quispel-Janssen (2024010314073775100_bib7) 2018; 24 Guzman (2024010314073775100_bib31) 2014; 9 Prichard (2024010314073775100_bib30) 1990; 14 Robinson (2024010314073775100_bib3) 2005; 353 Cedres (2024010314073775100_bib9) 2012; 77 Testa (2024010314073775100_bib17) 2011; 43 Blackledge (2024010314073775100_bib19) 2015; 16 George (2024010314073775100_bib33) 2022; 40 Nakajima (2024010314073775100_bib5) 2022; 28 McDonald (2024010314073775100_bib2) 1990; 249 Joseph (2024010314073775100_bib11) 2017; 30 Suzuki (2024010314073775100_bib10) 2009; 2 Sekido (2024010314073775100_bib12) 1995; 55 Bracken (2024010314073775100_bib22) 2009; 9 LaFave (2024010314073775100_bib25) 2015; 21 Burki (2024010314073775100_bib4) 2010; 375 Scheuermann (2024010314073775100_bib20) 2010; 465 Bueno (2024010314073775100_bib8) 2016; 48 Baas (2024010314073775100_bib6) 2021; 397 Leblay (2024010314073775100_bib15) 2017; 12 Sparmann (2024010314073775100_bib21) 2006; 6 Pandey (2024010314073775100_bib24) 2023; 4 Harrington (2024010314073775100_bib1) 1971; 232 Zauderer (2024010314073775100_bib28) 2022; 23 Carbone (2024010314073775100_bib18) 2012; 10 |
| References_xml | – volume: 397 start-page: 375 year: 2021 ident: 2024010314073775100_bib6 article-title: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)32714-8 – volume: 9 start-page: 773 year: 2009 ident: 2024010314073775100_bib22 article-title: Polycomb group proteins: navigators of lineage pathways led astray in cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc2736 – volume: 23 start-page: 758 year: 2022 ident: 2024010314073775100_bib28 article-title: EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(22)00277-7 – volume: 15 start-page: 550 year: 2014 ident: 2024010314073775100_bib32 article-title: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 publication-title: Genome Biol doi: 10.1186/s13059-014-0550-8 – volume: 232 start-page: 54 year: 1971 ident: 2024010314073775100_bib1 article-title: Asbestos and mesothelioma in man publication-title: Nature doi: 10.1038/232054a0 – volume: 28 start-page: 446 year: 2022 ident: 2024010314073775100_bib5 article-title: FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-1466 – volume: 14 start-page: 181 year: 1990 ident: 2024010314073775100_bib30 article-title: A three-dimensional model to analyze drug-drug interactions publication-title: Antiviral Res doi: 10.1016/0166-3542(90)90001-N – volume: 54 start-page: 5547 year: 1994 ident: 2024010314073775100_bib13 article-title: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma publication-title: Cancer Res – volume: 24 start-page: 84 year: 2018 ident: 2024010314073775100_bib7 article-title: Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-1172 – volume: 16 start-page: 643 year: 2015 ident: 2024010314073775100_bib19 article-title: Targeting Polycomb systems to regulate gene expression: modifications to a complex story publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm4067 – volume: 9 start-page: e92444 year: 2014 ident: 2024010314073775100_bib31 article-title: ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays publication-title: PLoS One doi: 10.1371/journal.pone.0092444 – volume: 105 start-page: 18507 year: 2008 ident: 2024010314073775100_bib29 article-title: Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0806213105 – volume: 10 start-page: 565 year: 2015 ident: 2024010314073775100_bib14 article-title: High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000471 – volume: 2 start-page: 181 year: 2009 ident: 2024010314073775100_bib10 article-title: Activation of the PI3K-AKT pathway in human malignant mesothelioma cells publication-title: Mol Med Rep – volume: 140 start-page: 87 year: 2020 ident: 2024010314073775100_bib27 article-title: A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma publication-title: Lung Cancer doi: 10.1016/j.lungcan.2019.12.018 – volume: 104 start-page: 65 year: 2017 ident: 2024010314073775100_bib26 article-title: A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: the Ontario clinical oncology group publication-title: Lung Cancer doi: 10.1016/j.lungcan.2016.12.004 – volume: 375 start-page: 626 year: 2010 ident: 2024010314073775100_bib4 article-title: Health experts concerned over India's asbestos industry publication-title: Lancet doi: 10.1016/S0140-6736(10)60251-6 – volume: 10 start-page: 179 year: 2012 ident: 2024010314073775100_bib18 article-title: BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs publication-title: J Transl Med doi: 10.1186/1479-5876-10-179 – volume: 4 start-page: 100915 year: 2023 ident: 2024010314073775100_bib24 article-title: Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma publication-title: Cell Rep Med doi: 10.1016/j.xcrm.2022.100915 – volume: 21 start-page: 1344 year: 2015 ident: 2024010314073775100_bib25 article-title: Loss of BAP1 function leads to EZH2-dependent transformation publication-title: Nat Med doi: 10.1038/nm.3947 – volume: 217 start-page: e2019157 year: 2020 ident: 2024010314073775100_bib23 article-title: Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice publication-title: J Exp Med doi: 10.1084/jem.20191257 – volume: 30 start-page: 246 year: 2017 ident: 2024010314073775100_bib11 article-title: Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X publication-title: Mod Pathol doi: 10.1038/modpathol.2016.188 – volume: 12 start-page: 724 year: 2017 ident: 2024010314073775100_bib15 article-title: BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.12.019 – volume: 43 start-page: 668 year: 2011 ident: 2024010314073775100_bib16 article-title: The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma publication-title: Nat Genet doi: 10.1038/ng.855 – volume: 465 start-page: 243 year: 2010 ident: 2024010314073775100_bib20 article-title: Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB publication-title: Nature doi: 10.1038/nature08966 – volume: 6 start-page: 846 year: 2006 ident: 2024010314073775100_bib21 article-title: Polycomb silencers control cell fate, development and cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc1991 – volume: 40 year: 2022 ident: 2024010314073775100_bib33 article-title: Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms publication-title: J Clin Oncol doi: 10.1200/JCO.2022.40.16_suppl.3122 – volume: 43 start-page: 1022 year: 2011 ident: 2024010314073775100_bib17 article-title: Germline BAP1 mutations predispose to malignant mesothelioma publication-title: Nat Genet doi: 10.1038/ng.912 – volume: 249 start-page: 844 year: 1990 ident: 2024010314073775100_bib2 article-title: Asbestos and carcinogenicity publication-title: Science doi: 10.1126/science.2168090 – volume: 353 start-page: 1591 year: 2005 ident: 2024010314073775100_bib3 article-title: Advances in malignant mesothelioma publication-title: N Engl J Med doi: 10.1056/NEJMra050152 – volume: 55 start-page: 1227 year: 1995 ident: 2024010314073775100_bib12 article-title: Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer publication-title: Cancer Res – volume: 77 start-page: 192 year: 2012 ident: 2024010314073775100_bib9 article-title: Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM) publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.02.022 – volume: 48 start-page: 407 year: 2016 ident: 2024010314073775100_bib8 article-title: Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations publication-title: Nat Genet doi: 10.1038/ng.3520 |
| SSID | ssj0002774563 |
| Score | 2.2704158 |
| Snippet | Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune... Malignant mesothelioma is a highly aggressive tumor with a survival of only 4–18 months after diagnosis. Treatment options for this disease are limited. Immune... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 18 |
| SubjectTerms | Animals Biomarkers Enhancer of Zeste Homolog 2 Protein - genetics Humans Lung Cancer Lung Neoplasms - drug therapy Melanoma - drug therapy Mesothelioma - drug therapy Mesothelioma, Malignant Mice Preclinical Models Small Molecule Agents Translational Research Tumor Suppressor Proteins - genetics Ubiquitin Thiolesterase - genetics |
| Title | Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38054839 https://www.proquest.com/docview/2898954601 https://pubmed.ncbi.nlm.nih.gov/PMC10763530 |
| Volume | 4 |
| WOSCitedRecordID | wos001154251800002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2767-9764 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002774563 issn: 2767-9764 databaseCode: DOA dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2767-9764 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002774563 issn: 2767-9764 databaseCode: M~E dateStart: 20210101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6lBVW9VLxJgWiRuEUu9nptr48lalqhJqpKQQEhWev1mloKTpSXyoUrf5uZ9SNOAwIOXCzLj7W13_jz7OzMt4S88sMgZszhlh-H3OIqCC3puMpyZRLr1AYX3dStfTgPhkMxGoUXrdaPqhZmNQ7yXNzchNP_CjUcA7CxdPYf4K4bhQOwD6DDFmCH7V8BD184jHY1ZvleZ3FWeYQnn86YmSnon_YvcRnzd9-w7M_oNGPQ483xhWMlGgUlMD1gAP75F0yS6Q70HKu0xtmkpPC1roHSs26pFoT5641Sk3XwXSblitdvMwy3z-rfwDm8TBl-HVbS_GYuK0-KMPqpXM7kqmuSwOtAUJVBnFkfq59uGbNg3MQsCh7ThttYAPwMnhBvEjHfsreCVAuC3uZ6D-sX6paOepc9i5lJab95PaAz_WqwdgX4p6LQTrolsl2d2iF3WOCFSI-D7-tgHQMn2fPdsgIMHvz6l4_dJ3tVQ5tuztbY5XYKbsOnubpHDsrBCD0ujOg-aen8AdkblOkWD8nnypbo2pboJKVoSxRwomhLNJvThi3RLKebtkRrW6JNW3pE3vdPrnpnVrkch6W4wxdWypRSOgaO1wFPPM_zk0QoO7V9pgXXbuA6PObSU0KCXx2kXuIo25YiSUIULEjcx2Q3n-T6KaHghUtbwVgCBfKE44fKT2MmHFdKT4ZctQmvei9SpVY9LpkyjsyY1RMR9n-E_R9B_0fMjbD_2-Sovm1aiLX86YaXFTQR0CrOlclcT5bziOGyqh73badNnhRQ1U1WGLeJ2ACxvgAl2zfP5Nm1kW53bBSAdO3D3zb6jOyvv5jnZHcxW-oX5K5aLbL5rEN2gpHomMBRx5joT9sYraY |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combined+Inhibition+of+EZH2+and+FGFR+is+Synergistic+in+BAP1-deficient+Malignant+Mesothelioma&rft.jtitle=Cancer+research+communications&rft.au=Badhai%2C+Jitendra&rft.au=Landman%2C+Nick&rft.au=Pandey%2C+Gaurav+Kumar&rft.au=Song%2C+Ji-Ying&rft.date=2024-01-03&rft.eissn=2767-9764&rft.volume=4&rft.issue=1&rft.spage=18&rft_id=info:doi/10.1158%2F2767-9764.CRC-23-0276&rft_id=info%3Apmid%2F38054839&rft.externalDocID=38054839 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2767-9764&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2767-9764&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2767-9764&client=summon |